Sarepta data suggest 3-year benefit in muscular dystrophy

July 10, 2014 12:53 PM

3 0

Sarepta data suggest 3-year benefit in muscular dystrophy

In April, Sarepta said it received guidance from the FDA that provided a path for seeking regulatory approval, driving shares up 40 percent. That came just five months after the stock lost 64 percent of its value in one day after the company said regulators considered its plan to file for approval premature. Sarepta's market value was about $1 billion as of Wednesday's market close.

In April, Sarepta said it received guidance from the FDA that provided a path for seeking regulatory approval, driving shares up 40 percent. That came just five months after the stock lost 64 percent of its value in one day after the company said regulators considered its plan to file for approval p...

Also read: Apple tells feds ‘new entrants’ to auto industry should get same testing rights as incumbents

Read more

To category page

Loading...